Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey

Wickersham, Jeffrey A.; Meyer, Jaimie P.; Shenoi, Sheela; Altice, Frederick L.; Barakat, Lydia; Virata, Michael; Olivares, Miriam; Maviglia, Francesca; Khati, Antoine; Shrestha, Roman

doi:10.3389/fmed.2022.886936

Cited by 13 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the respondents, 85.4% were prone to vaccination and it has not been influenced by media. It has been reported that they would be more willing to receive a COVID‐19 vaccine if it was recommended by their doctor (61.5%) or if their doctor mentioned that they had been vaccinated themselves 16 . Our survey timing was vaccination first phase in Spain.…”

Section: Discussionmentioning

confidence: 99%

Attitudes and perceptions about COVID‐19 vaccination in the population with chronic HIV infection: A systematic review

Shirley,

Francisco,

Elisabet

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and AimsThe coronavirus disease 2019 (COVID‐19)‐infected population has been increasing during the last 3 years worldwide. Moreover, simultaneously, COVID‐19 vaccine clinical trials were launched. By the end of 2020, the Food and Drug Administration had authorized the emergency use of two messenger RNA vaccines against COVID‐19. These fast‐track vaccine approvals have produced controversy about their safety and efficacy. The purpose of this research was to discover attitudes and perceptions regarding vaccination against COVID‐19 disease among vulnerable groups such as human immunodeficiency virus (HIV)‐infected patients.MethodsBetween June 2, 2021 and March 4, 2022, we conducted a cross‐sectional study through a survey of high‐risk patients with severe COVID‐19, such as HIV‐infected patients in the Infectious Diseases Unit (Hospital Clínico Universitario San Juan, Alicante). For the data collection strategy, a nonprobabilistic snowball sampling was adopted. A structured, anonymous, self‐administered questionnaire was developed in which questions and statements were designed to evaluate their attitudes and perceptions about COVID‐19 vaccination. Descriptive and bivariate analyses were performed for the obtained data.ResultsForty‐eight participants were recruited with a mean age of 51.5 ± 11.9 years. Thirty‐nine of them (81.3%) were male. The acceptance rate of COVID‐19 vaccination was extremely high (95.7%). Bivariate analysis showed older patients significantly received a higher proportion of vaccine doses at the time of the survey (p = 0.047). Older patients were more aware of the vaccine safety controversy (61.1%) compared to younger patients (p = 0.054). There were no other significant differences between groups among questions regarding safety, efficacy, or attitudes about COVID‐19 vaccination.ConclusionAn extremely high degree of acceptance for COVID‐19 vaccination was reported. Older patients were more aware of the vaccine safety controversy. Medical staff is the most trustworthy source of information, far above all other sources. Social networks and opinion leaders have not been shown to significantly influence our population.

show abstract

Section: Discussionmentioning

confidence: 99%

Attitudes and perceptions about COVID‐19 vaccination in the population with chronic HIV infection: A systematic review

Shirley,

Francisco,

Elisabet

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…2,20,21 When COVID-19 vaccines became public, health authorities found public acceptance and dispersion of vaccines were suboptimal due to mistrust and safety and efficacy concerns. 22 For PLWH who had compromised immune systems, concerns about vaccine safety and efficacy were amplified. 7 We conducted this analysis to provide insight on the impact of COVID-19 directly from PLWH based on a sample of 5 Medical Monitoring Project (MMP) sites across 2 project cycle years of data collection, from mid-2020 through mid-2022.…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 on People Living With HIV: Data From Five Medical Monitoring Project Sites, 2020–2022

Erly,

Menza,

Granillo

et al. 2024

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Background: The COVID-19 pandemic disrupted global economic and healthcare systems. People living with HIV (PLWH) represent a marginalized and stigmatized population who may have been particularly impacted. The purpose of this analysis was to describe the impact of the COVID-19 pandemic on PLWH in the United States. Setting: United States. Methods: We analyzed surveys of behavioral and clinical characteristics of PLWH residing in five states that participated in the Medical Monitoring Project between 2020 and 2022. We described the impact of COVID-19 illness, testing and diagnoses, receipt of medical care, social service access, employment, and preventive measures by project site and demographic characteristics. Results: Unweighted data from 1715 PLWH were analyzed. A high proportion of PLWH had medical care disrupted by the pandemic; 31% of PLWH missed medical appointments, 26% missed routine labs, and 7% missed antiretroviral therapy doses. 30% of PLWH reported losing wages and 19% reported difficulty in accessing social services. Overall, 88% reported receiving at least one dose of COVID-19 vaccine, but vaccine uptake was low among younger, Black and Hispanic or Latina/o/x PLWH. Conclusion: This descriptive analysis reinforces previous findings that show that COVID-19 negatively impacted PLWH and their ability to obtain medical care. Additional efforts will be critical to ameliorating the longer-term impacts of COVID-19 on the health of PLWH and supporting PLWH through future pandemics and healthcare system disruptions.

show abstract

Section: Introductionmentioning

confidence: 99%

“…6,7 Despite the vaccine effectiveness, the rates of COVID-19 vaccine hesitancy among PLHIV ranges from 16%-91% depending on the study settings and the points of time when the studies were conducted. [8][9][10][11][12][13] The main reasons for vaccine hesitation were concerns about safety, 8-13 efficacy [8][9][10][11][12][13] and the impact of the vaccines on antiretroviral therapy (ART) efficacy. 11 In addition, hesitation was found to be associated with medical mistrust, feelings of vaccines being experimental, obtaining information from social media, political conservativeness, and lower education level.…”

Section: Introductionmentioning

confidence: 99%

“…11 In addition, hesitation was found to be associated with medical mistrust, feelings of vaccines being experimental, obtaining information from social media, political conservativeness, and lower education level. [8][9][10][11][12][13] Previous studies among PLHIV have demonstrated safety profiles of various COVID-19 vaccine types including inactivated, 8,14-18 viral vector, [19][20][21] and mRNA vaccines. [21][22][23][24] Overall, most common adverse effects (AEs) of the vaccines were local injection site reactions and systemic reactions including fatigue, fever, myalgia and headache.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety profiles of homologous and heterologous regimens containing three major types of COVID-19 vaccine among people living with HIV

Khawcharoenporn,

Hanvivattanakul

2023

Int J STD AIDS

View full text Add to dashboard Cite

Background Existing data on adverse effects (AEs) of homologous and heterologous COVID-19 vaccine regimens among people living with HIV (PLHIV) are limited. Methods A prospective cohort study was conducted among Thai PLHIV during 2021–2022. Vaccine types and AEs were collected using an online survey. Results Of the 398 vaccinated PLHIV, 92% had CD4 count ≥200 cells/µL and 96% were virologically suppressed at enrolment; 38% received two doses and 62% received three doses of COVID-19 vaccines. Inactivated, viral vector and mRNA were the most common vaccine types received as the first, second, and booster doses, respectively. For the first and second vaccine doses, the most common AEs were fever (15% and 11%) and injection site pain (11% and 11%). The mRNA vaccine significantly caused more overall AEs, injection pain, fatigue, and rashes than the other two types. For a booster dose, viral vector vaccine significantly caused more injection site pain and headache than the other two types. The majority of AEs of the first, second and booster doses spontaneously recovered without treatment. By multivariable analysis, receipt of viral vector or mRNA vaccine and age less than 40 years were independently associated with AEs of the primary series vaccines, while having AEs from the previous dose and female sex were independent factors associated with AEs of a booster vaccine. Conclusions Our study suggested the safety of homologous and heterologous regimens containing the three types of COVID-19 vaccines among PLHIV and identified those who required close monitoring for vaccine AEs.

show abstract

Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey

Cited by 13 publications

References 14 publications

Attitudes and perceptions about COVID‐19 vaccination in the population with chronic HIV infection: A systematic review

Attitudes and perceptions about COVID‐19 vaccination in the population with chronic HIV infection: A systematic review

Impact of COVID-19 on People Living With HIV: Data From Five Medical Monitoring Project Sites, 2020–2022

Safety profiles of homologous and heterologous regimens containing three major types of COVID-19 vaccine among people living with HIV

Contact Info

Product

Resources

About